UPR Stock Overview
Operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Uniphar plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.76 |
| 52 Week High | €2.56 |
| 52 Week Low | €1.66 |
| Beta | 0.79 |
| 11 Month Change | -12.00% |
| 3 Month Change | -24.14% |
| 1 Year Change | -4.86% |
| 33 Year Change | -51.91% |
| 5 Year Change | 91.55% |
| Change since IPO | 82.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| UPR | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 2.6% | 1.4% | 1.7% |
| 1Y | -4.9% | -22.1% | 8.3% |
Return vs Industry: UPR exceeded the UK Healthcare industry which returned -22.6% over the past year.
Return vs Market: UPR underperformed the UK Market which returned 8% over the past year.
Price Volatility
| UPR volatility | |
|---|---|
| UPR Average Weekly Movement | 3.3% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: UPR has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: UPR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 3,000 | Ger Rabbette | www.uniphar.ie |
Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally. The company operates through three divisions: Medtech, Pharma, and Supply Chain & Retail. The Medtech division offers outsourced sales; and marketing, distribution, and support services to medical device manufacturers.
Uniphar plc Fundamentals Summary
| UPR fundamental statistics | |
|---|---|
| Market cap | UK£475.33m |
| Earnings (TTM) | UK£37.54m |
| Revenue (TTM) | UK£2.23b |
12.7x
P/E Ratio0.2x
P/S RatioIs UPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UPR income statement (TTM) | |
|---|---|
| Revenue | €2.68b |
| Cost of Revenue | €2.27b |
| Gross Profit | €408.69m |
| Other Expenses | €363.52m |
| Earnings | €45.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 15.24% |
| Net Profit Margin | 1.68% |
| Debt/Equity Ratio | 68.5% |
How did UPR perform over the long term?
See historical performance and comparison